Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease



Status:Completed
Conditions:Alzheimer Disease, Cognitive Studies
Therapuetic Areas:Neurology, Psychiatry / Psychology
Healthy:No
Age Range:55 - Any
Updated:2/2/2019
Start Date:September 2013
End Date:July 2017

Use our guide to learn which trials are right for you!

The goal of this study is to create new retinal imaging processing software useful for the
development of novel retinal biomarkers of cognitive impairment associated with Alzheimer's
disease (AD).


Inclusion Criteria:

1. Result of the standard neuropsychological assessment

2. Are men or postmenopausal women, at least 55 years of age. Postmenopausal women are
defined as women who have had a hysterectomy and/or bilateral oophorectomy; or who
have been amenorrheic for at least 2 years;

3. Fluency in English

4. Participants in mild cognitive impairment (MCI)/prodromal and mild-to-moderate
dementia groups must assign a surrogate for purposes of informed consent and help with
protocol compliance.

Exclusion Criteria:

1. Known or suspected diagnosis of non-AD, associated dementia;

2. Major ophthalmologic comorbidities: Ruptured globe, retinal vascular occlusive
disease, retinal artery occlusion, anterior ischemic optic neuropathy, media
opacification due to corneal abnormalities or cataract that prevent ocular and OCT
examination, glaucoma, wet (neovascular) age-related macular degeneration, history of
intravitreal injections, and macular edema. If two eyes satisfy the inclusion
criteria, both eyes will be included in the study.
We found this trial at
1
site
2301 Erwin Rd
Durham, North Carolina 27710
919-684-8111
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
?
mi
from
Durham, NC
Click here to add this to my saved trials